Generic drug rule
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed rule to modify Hatch/Waxman patent procedures should be finalized this spring, Commissioner Mark McClellan, MD/PhD, said during a March 6 House Appropriations Subcommittee hearing on FDA's budget. President Bush announced the rule in October (1"The Tan Sheet" Oct. 28, 2002, p. 10)...
You may also be interested in...
Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.